3Berenbaum F. New horizons and perspectives in the treat- ment of osteoarthritis[ J]. Arthritis Res Ther,2008,10 Sup- pl 2:S1.
4Sarzi - Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthfi- tis :an overview of the disease and its treatment strategies [ J ]. Semin Arthritis Rheum ,2005,35 ( 1 Suppl 1 ) : 1 - 10.
5Singh G,Fort JG,Goldstein JL,et al. Celecoxib versus naprox- en and diclofenac in osteoarthritis patients: SUCCESS - I Study[J]. Am J Med,2006,119(3) :255 -266.
7Bijlsma JW. Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk [J ]. Ned Tijdschr Geneeskd, 2004, 148 (44) : 2162 - 2164.
8Krzeski P, Buckland - Wright C, BOlint G, et al. Develop- ment of musculoskeletal toxicity without clear benefit after administration of PG -116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis : a randomized, 12 - month, double - blind, placebo - controlled study [ J ]. Arthritis Res Ther, 2007,9 ( 5 ) : R109.
9Jordan KM, Arden NK, Doherty M, et al. EULAR Recom- mendations 2003 : an evidence based approach to the man- agement of knee osteoarthritis : Report of a Task Force of the Standing Committee for International Clinical Studies Inclu- ding Therapeutic Trials (ESCIS1T) [ J ]. Ann Rheum Dis, 2003,62 (12) : 1145 - 1155.
10Monfort J, Martel - Pellctier J, Pelletier JP. Chondroitin sul- phate for symptomatic osteoarthritis : critical appraisal of me- ta-analyses [ J ]. Curr Med Res Opin, 2008,24 ( 5 ) : 1303 - 1308.
